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Objectives: Whether new medical technology is implemented may depend 
on the balance between costs and effects, but also on practical constraints. 
Examples are a fixed health care budget and a maximum clinically acceptable 
risk of adverse events. However, the impact of compliance with such constraints 
cannot be handled explicitly in the current value of information (VOI) framework. 
Our objective was to demonstrate proper handling of constraints by extending 
the VOI framework through separation of cost, effect, and constraint compo-
nents. MethOds: The proposed VOI extension was investigated in a simulation 
study comparing two hypothetical drugs and their side effects. The VOI exten-
sion was also applied to a clinical study concerning the cost-effectiveness of 
carotid intima-media thickness measurements to improve treatment guidance 
of patients at high risk of cardiovascular disease. Results of the standard VOI 
analysis, considering only costs and effects, were compared with results from the 
extended VOI analysis explicitly considering constraints. Results: Standard VOI 
results may under- or overestimate the value of additional research compared 
to extended VOI results. In our clinical example, with penalties of $2 and $5 
per dollar budget exceedance, standard values for the Expected Value of Perfect 
Information (EVPI) of $24, and $1,490 were found, with corresponding values of 
$239, and $565 for the extended EVPI. Ignoring the budget constraint in the stand-
ard EVPI analysis therefore resulted in a underestimation of $214 ($2 penalty) and 
an overestimation of $925 ($5 penalty) of the EVPI per patient. cOnclusiOns: 
When decision-maker’s criteria go beyond costs and effects, standard VOI results 
may not reflect the actual value of additional research accurately and may there-
fore jeopardize optimal research prioritization. Determination of the extended 
VOI, through separation of cost, effect, and constraint components, is straightfor-
ward and can support optimal research prioritization regardless of the complexity 
of the decision criteria considered.
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Objectives: Meta-analysis combines results from independent studies to pro-
duce robust statistical estimates. This technique is widely used in health care 
to synthesise treatment effects from clinical studies. However, when dealing 
with rare events such as rare adverse events, existing meta-analysis methods 
might not produce good treatment effect estimates, especially when there is no 
event occurrence in one or both arms of a study. The objective of this study is to 
compare the performance of various methods in estimating effect size for rare 
events. MethOds: An assessment of meta-analysis methods providing pooled 
odds-ratios as effect size estimates was conducted for different scenarios. The 
Inverse Variance Weighted, Peto, Mantel-Haenszel and logistic methods were 
assessed, with constant, “treatment arm” or empirical continuity corrections 
added when needed. The scenarios were created using different values of odds-
ratio, baseline risk, and group imbalance. For each scenario 5,000 simulations of 
10 studies were generated using R software. Coverage, bias and statistical power 
were used to compare the methods. Results: The most commonly used conti-
nuity correction is outperformed in every scenario by the two other corrections. 
The inverse variance method, most commonly used in meta-analysis, performs 
poorly when the event probability is smaller than 0.10: it is not recommended for 
sparse data. Peto’s method performs well in some scenarios but leads to biased 
results with high odds ratios and high imbalance. The logistic method is highly 
biased when baseline risk is low and true odds ratio is high. Under other scenarios 
it performs well but is most often outperformed by other methods. The Mantel-
Haenszel method with empirical correction performs constantly well over the 
scenarios. cOnclusiOns: These findings may be used to develop guidelines on 
when to use which method for conducting meta-analysis with rare events. Next 
steps will be to assess the use of mixed models and Bayesian techniques.
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Objectives: Propensity score matching (PSM) is an approach commonly used 
when treatment and control groups are thought to be different on key study vari-
ables. When the control group is larger than the treatment group, (as large as 20:1) 
a good match might be easy to obtain. However, differences may exist between the 
matched controls and the unmatched controls, indicating poor generalizability 
of study results. MethOds: Groups for the analysis are the unmatched controls 
(UM), the matched controls (MC) and the treatment cohort (TRT). Analysis methods 
for these groups in a fully crossed method and interpretation of the results will 
determine internal (IV) and external validity (EV). Analysis comparing the groups 
against the outcomes variable will determine if variables need to be controlled 
for in models that may be developed. Results: After the PSM is conducted MC 
and TRT groups should be compared on the matched variables. Differences at this 
stage would indicate a poor match and a low level of IV. MC and UM should also 
be compared on the variables used for matching, as well as the outcome variables 
of interest. Significant differences on the matched variables would indicate low 
EV and poor generalizability of results, while differences of MC and UM groups 
and UM and TRT groups on the outcome variables would indicate that statisti-
cal models would need to address covariates as potential confounding effects 
would be present. Analysis methods can be fit statistics (chi-square or equiva-
lence tests) or typical inferential methods with adjusted p-values greater than 
0.05. cOnclusiOns: It is important that research studies maintain good IV and 
EV. This is often complicated in research where the controls vastly outnumber the 
treatment group. Proper statistical analysis can go a long way to test and clarify 
data to make the results as meaningful as possible.
(IPD) is available. In many situations, especially when Indirect Comparison (IC) 
methods are required to estimate head-to-head effects, it is often the case that 
IPD is only available for one trial, and summary data for the other. A variety of 
potential methods are evaluated for the adjustment of such summary data using 
simulation methodology. MethOds: A review of HTA submissions to NICE in 
which both ICs were used and in which trials were subject to treatment switch-
ing was undertaken. A series of simulation studies were undertaken to assess the 
potential level of bias associated with the methods that are most commonly used 
for the analysis of such trials. Two broad approaches to adjusting summary data 
for treatment switching were then evaluated on the simulated data – calculation of 
Adjustment Factors (AFs), and re-creation and analysis (including bootstrapping) 
of IPD using scanned survival curves. Results: The most commonly reported 
methods of analysis for studies only presenting summary data were Intention-
to-Treat (ITT) and Per Protocol (PP) analyses. Results from the simulation stud-
ies indicated that these may be subject to between 0.5% and 140% levels of bias 
depending on trial characteristics, and that the use of AFs or re-created IPD had 
potential scope for reducing this. cOnclusiOns: Treatment switching can be 
associated with considerable levels of bias, and methods for adjusting using sum-
mary data, can go some way to compensating for this when IPD is not available 
as is often the case in Indirect Comparisons (IC). Further extension to a Network 
Meta-Analysis (NMA) setting is under investigation.
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Objectives: Large scale survey data presents a number of challenges to imputa-
tion, not least the high number of variables and complexity of the data set. Data 
may suffer from sparsity in responses, and some questions may be conditional 
upon previous responses. In addition, survey data commonly contain results from 
multiple rating scales, which are summed (either directly or weighted) during 
analysis. We aim to develop a method for the multiple imputation of missing 
data from complex surveys. MethOds: We propose an adaptation of multiple 
imputation for survey data which contains multiple rating scales, whereby scale 
summary scores are used within the prediction models. The method is applied to 
data gathered from a large multinational survey, with data sets from 9 countries. 
Analysis uses a logistic regression model on each of the 9 data sets, and results 
are compared from a complete case analysis approach with those from multiple 
imputation. Results: The proposed approach reduces the size of the prediction 
models from 135 predictors to a maximum of 72. Distributions of imputed data are 
seen to be consistent with observed data. Results from the regression analysis with 
multiple imputation are similar to, but show lower standard errors than, results 
for complete case analysis; for the same regression models a 39% reduction in 
the standard error is observed. cOnclusiOns: Our adaptation makes multiple 
imputation practical for large scale survey data with multiple rating scales. For 
the data considered, analysis of the multiply imputed data shows greater power 
and efficiency than complete case analysis. The adaptation of multiple imputation 
makes better use of available data and can yield substantively different results 
from simpler, less valid techniques.
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Objectives: Subsequent therapies can confound the evaluation of overall survival 
(OS) in oncology trials. We evaluated the application of rank-preserving structural 
failure time modeling for the estimation of OS effects in presence of subsequent 
therapies through Monte Carlo simulations. Results were demonstrated for a clini-
cal trial: the Lux Lung 1 study of afatinib vs. placebo in non-small cell lung can-
cer. MethOds: In accelerated failure time models, covariates are assumed to affect 
survival times rather than hazard rates. Counterfactual survival times can therefore 
be computed, i.e. how long patients would have survived without the investigational 
or subsequent therapies. The parameters of structural failure time models can be 
obtained by G-estimation, whereby counterfactual survival times are calculated 
with hypothetical treatment effects and OS is compared between treatment arms. 
The G-estimate is the set of hypothetical effects that generate the most similar 
survival in both study arms. Branson & Whitehead (2002) developed an alternative 
estimation method for trials with cross-in from placebo to active treatment based 
on iterative parametric regressions; we extend this framework to the application 
with subsequent therapies. Results: Simulation showed that standard methods 
are biased in the presence of subsequent therapies affecting overall survival. This 
includes intent-to-treat analysis, censoring at start of subsequent therapies and 
subgroup analysis in patients never receiving subsequent therapy. G-estimation 
often failed to identify parameter values when more than one treatment effect was 
included in the model. Iterative parameter estimation produced unbiased estimates 
in simulation studies and predicted a small numeric but non-significant survival 
benefit of afatinib. cOnclusiOns: Structural failure time models can be useful to 
obtain unbiased estimates of OS in presence of subsequent therapies. However the 
assumption of proportionality in survival times cannot be tested empirically and 
non-standard estimation procedures are required.
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